A Phase 3 trial investigating the herbal medicine Qurs e Fishar for Hypertension reached its primary completion milestone on 2025-06-30. The study, NCT06852079, is evaluating the safety and efficacy of the intervention in 119 participants with mild to moderate hypertension.
Background
Hypertension, or high blood pressure, is a common chronic condition that significantly increases the risk of heart disease, stroke, and kidney failure. Effective management is crucial for preventing these severe health outcomes. While conventional pharmaceutical treatments are widely available, there is ongoing interest in traditional and herbal medicines, particularly in regions where they are culturally significant and accessible. Qurs-e-Fishar, a product from Hamdard Laboratories (Waqf) Pakistan, is an herbal medicine intended to treat mild to moderate hypertension, comprising Rauwolfia serpentina. Studies like this Phase 3 trial are important for evaluating the safety and efficacy of such interventions within a structured clinical research framework.
Trial design
This completed study, identified as Phase PHASE3, enrolled 119 adult participants aged 30 to 60 years with Hypertension. It is an Open-label, Single-Arm, Interventional, Multicenter study conducted in Pakistan. Participants were prescribed the study product for 12 weeks (84 days). The primary endpoint for the trial is defined as a reduction in diastolic blood pressure to less than 130 / 80 mmHg at the end of the study period (accepted by WHO), or a fall of 20 / 10 mmHg or more in diastolic blood pressure.
What this means
The primary completion of this Phase 3 trial signifies that data collection for the main outcome measures has concluded for all enrolled participants. This is a critical step in the clinical trial process, indicating that the study is progressing towards the analysis and eventual dissemination of its findings. For patients with hypertension, particularly those in Pakistan who might consider traditional or herbal remedies, the completion of this trial suggests that results regarding the safety and efficacy of Qurs e Fishar may become available in the future, providing evidence-based information on this treatment option. However, it is important to note that results are not yet published.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The event date of 2025-06-30 for the study NCT06852079, titled "Safety & Efficacy of Qurs e Fishar in Mild to Moderate Hypertensive Patients in Pakistan", was recorded on clinicaltrials.gov.